アプタマー市場

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2021年11月

アプタマー市場:製品タイプ（DNA、RNA、XNA）、テクノロジー（SELEX）、用途（治療、診断、R＆D）、エンドユーザー（製薬、バイオテクノロジー企業、学術および政府研究所、CRO） – 2026年までの世界予測

Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) – Global Forecast to 2026

–

–

The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.
“SELEX is the largest end-user segment in the aptamers market in 2020”
Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.
“Diagnostic segment is anticipated to witness the fastest growth during the forecast period.”
Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.
“Asia Pacific region is anticipated to witness the fastest growth during the forecast period.”
The aptamers market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.

The break-down of primary participants is as mentioned below:
• By Company Type – Tier 1: 35%, Tier 2: 40%, and Tier 3: 25%
• By Designation – C-level: 45%, Director-level: 30%, and Others: 25%
• By Region – North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 5%
Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan).
Research Coverage:
The report analyzes the aptamers market and aims at estimating the market size and future growth potential of various market segments, based on type, technology, application, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
 Market Penetration: Comprehensive information on the product portfolios of the top players in the aptamers market. The report analyzes this market by type, technology, application, end user and region
 Market Development: Comprehensive information on the lucrative emerging markets, by type, technology, application, end user and region
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the aptamers market
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the aptamers market

目次

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 MARKET SCOPE 27
FIGURE 1 APTAMERS MARKET 27
1.3.1 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 28
1.5 LIMITATION 28
1.6 STAKEHOLDERS 28
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.2 PRIMARY DATA 32
FIGURE 3 APTAMERS MARKET: BREAKDOWN OF PRIMARIES 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF APTAMERS IN THE MARKET 33
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020 34
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 35
FIGURE 6 APTAMERS MARKET: CAGR PROJECTIONS, 2021–2026 35
FIGURE 7 APTAMERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 36
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 36
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 37
FIGURE 9 DATA TRIANGULATION METHODOLOGY 38
2.5 INSIGHTS FROM PRIMARIES 39
FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS 39
2.6 RESEARCH ASSUMPTIONS 39
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 40
2.7 RISK ANALYSIS 40

3 EXECUTIVE SUMMARY 41
FIGURE 11 APTAMERS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 41
FIGURE 12 APTAMERS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 42
FIGURE 13 APTAMERS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 42
FIGURE 14 APTAMERS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 43
FIGURE 15 GEOGRAPHICAL SNAPSHOT: APTAMERS MARKET 43
4 PREMIUM INSIGHTS 45
4.1 APTAMERS MARKET OVERVIEW 45
FIGURE 16 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D
TO SUPPORT MARKET GROWTH 45
4.2 NORTH AMERICA: APTAMERS MARKET SHARE, BY TYPE & COUNTRY (2020) 46
FIGURE 17 DNA APTAMERS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN APTAMERS MARKET IN 2020 46
4.3 APTAMERS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 47
FIGURE 18 XNA APTAMERS SEGMENT WILL DOMINATE THE MARKET IN 2026 47
4.4 APTAMERS MARKET SHARE, BY END USER, 2020 47
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020 47
4.5 APTAMERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH FROM 2021 TO 2026 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
FIGURE 21 APTAMERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
TABLE 1 APTAMERS MARKET: IMPACT ANALYSIS 50
5.2.1 DRIVERS 51
5.2.1.1 Rising number of clinical trials to develop aptamer-based therapeutics 51
TABLE 2 LIST OF APTAMERS/APTAMER-BASED THERAPEUTICS IN PIPELINE 51
5.2.1.2 Rising awareness of the advantages of aptamers over antibodies 52
5.2.1.3 Investments in pharmaceutical R&D 52
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 53
TABLE 3 R&D SPENDING OF PROMINENT PHARMACEUTICAL COMPANIES IN 2019 & 2020 (USD BILLION 53
5.2.1.4 Rising prevalence of chronic and rare diseases 53
FIGURE 23 GLOBAL PREVALENCE OF CANCER, BY TYPE 54
5.2.2 RESTRAINTS 54
5.2.2.1 Low market acceptance as compared to antibodies 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Growth in the venture capital funding for research on aptamers 54
5.2.3.2 Growing collaborations with research institutes and pharmaceutical companies 55
5.2.4 CHALLENGES 55
5.2.4.1 Shortage of skilled & trained professionals 55
5.3 IMPACT OF COVID-19 OUTBREAK ON THE APTAMERS MARKET 56
FIGURE 24 APTAMERS MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021 (USD MILLION) 56
5.4 PIPELINE ANALYSIS 57
TABLE 4 THERAPEUTIC PIPELINE OF APTAMERS IN VARIOUS PHASES OF DRUG DEVELOPMENT 58
5.5 TECHNOLOGY ANALYSIS 58
5.6 PORTERS FIVE FORCES ANALYSIS 59
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 59
5.6.1 THREAT OF NEW ENTRANTS 59
5.6.2 THREAT OF SUBSTITUTES 59
5.6.3 BARGAINING POWER OF SUPPLIERS 59
5.6.4 BARGAINING POWER OF BUYERS 59
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 60
5.7 ECOSYSTEM ANALYSIS 60
FIGURE 25 APTAMERS MARKET: ECOSYSTEM ANALYSIS 60
5.8 VALUE CHAIN ANALYSIS 61
FIGURE 26 VALUE CHAIN: APTAMERS MARKET 61
5.9 PATENT ANALYSIS 62
5.9.1 PATENT PUBLICATION TRENDS 62
FIGURE 27 PATENT PUBLICATION TRENDS: 2010–2021 62
5.9.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES)
FOR APTAMER PATENTS 63
TABLE 6 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR APTAMER PATENTS 63
FIGURE 28 JURISDICTION ANALYSIS FOR THE US (2014–2021) 63
6 APTAMERS MARKET, BY TYPE 64
6.1 INTRODUCTION 65
TABLE 7 APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 65
6.2 DNA APTAMERS 65
6.2.1 INCREASING USE OF DNA APTAMERS AND THEIR WIDE AVAILABILITY BOOSTS SEGMENT GROWTH 65
TABLE 8 DNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION) 66
TABLE 9 NORTH AMERICA: DNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 66
TABLE 10 EUROPE: DNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 66
TABLE 11 ASIA PACIFIC: DNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 67

6.3 XNA APTAMERS 67
6.3.1 FOCUS ON DEVELOPING NEXT-GENERATION APTAMERS FOR SPECIFIC TARGETS TO BOOST SEGMENT GROWTH 67
TABLE 12 XNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION) 67
TABLE 13 NORTH AMERICA: XNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 68
TABLE 14 EUROPE: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 68
TABLE 15 ASIA PACIFIC: XNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 68
6.4 RNA APTAMERS 69
6.4.1 INCREASING RESEARCH ACTIVITIES FOR THE USE OF RNA APTAMERS BOOSTS SEGMENT GROWTH 69
TABLE 16 RNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION) 69
TABLE 17 NORTH AMERICA: RNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 69
TABLE 18 EUROPE: RNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 70
TABLE 19 ASIA PACIFIC: RNA APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 70
7 APTAMERS MARKET, BY TECHNOLOGY 71
7.1 INTRODUCTION 72
TABLE 20 APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 72
7.2 SELEX 72
7.2.1 SELEX IS THE MOST WIDELY USED TECHNOLOGY FOR APTAMERS SELECTION 72
TABLE 21 SELEX TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 73
TABLE 22 NORTH AMERICA: SELEX TECHNOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 73
TABLE 23 EUROPE: SELEX TECHNOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 73
TABLE 24 ASIA PACIFIC: SELEX TECHNOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 74
7.3 OTHER TECHNOLOGIES 74
TABLE 25 OTHER TECHNOLOGIES MARKET, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 26 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 75
TABLE 27 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 75
TABLE 28 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 75

8 APTAMERS MARKET, BY APPLICATION 76
8.1 INTRODUCTION 77
TABLE 29 APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 77
8.2 THERAPEUTICS DEVELOPMENT 77
8.2.1 PROMINENT PLAYERS OFFERING SERVICES FOR THERAPEUTICS DEVELOPMENT TO BOOST THE MARKET GROWTH 77
TABLE 30 APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY REGION,
2019–2026 (USD MILLION) 78
TABLE 31 NORTH AMERICA: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 32 EUROPE: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 33 ASIA PACIFIC: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 79
8.3 RESEARCH & DEVELOPMENT 79
8.3.1 INCREASING AVAILABILITY OF APTAMERS FOR ACADEMIC RESEARCH TO DRIVE MARKET GROWTH 79
TABLE 34 APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION,
2019–2026 (USD MILLION) 79
TABLE 35 NORTH AMERICA: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 80
TABLE 36 EUROPE: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 80
TABLE 37 ASIA PACIFIC: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 80
8.4 DIAGNOSTICS 81
8.4.1 THE INCREASING PREVALENCE OF DISEASES SUCH AS CANCER AND PRODUCT LAUNCHES ARE PROJECTED TO DRIVE THE SEGMENT GROWTH 81
TABLE 38 APTAMERS MARKET FOR DIAGNOSTICS, BY REGION,
2019–2026 (USD MILLION) 81
TABLE 39 NORTH AMERICA: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION) 82
TABLE 40 EUROPE: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD MILLION) 82
TABLE 41 ASIA PACIFIC: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD MILLION) 82
8.5 OTHER APPLICATIONS 83
TABLE 42 APTAMERS MARKET FOR OTHER APPLICATIONS, BY REGION,
2019–2026 (USD MILLION) 83
TABLE 43 NORTH AMERICA: APTAMERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 83
TABLE 44 EUROPE: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 84
TABLE 45 ASIA PACIFIC: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 84

9 APTAMERS MARKET, BY END USER 85
9.1 INTRODUCTION 86
TABLE 46 APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 86
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 86
9.2.1 PROMINENT PLAYERS OFFERING SERVICES FOR DRUG DEVELOPMENT TO DRIVE MARKET GROWTH 86
TABLE 47 APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION) 87
TABLE 48 NORTH AMERICA: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 87
TABLE 49 EUROPE: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 50 ASIA PACIFIC: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 88
9.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 88
9.3.1 COLLABORATIVE EFFORTS AMONG COMPANIES & RESEARCH INSTITUTES WILL DRIVE THE GROWTH OF THE MARKET 88
TABLE 51 APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 89
TABLE 52 NORTH AMERICA: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 89
TABLE 53 EUROPE: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 89
TABLE 54 ASIA PACIFIC: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 90
9.4 CONTRACT RESEARCH ORGANIZATIONS 90
9.4.1 RESEARCH PARTNERSHIPS BETWEEN PHARMA PLAYERS AND CONTRACT ORGANIZATIONS DRIVE MARKET GROWTH 90
TABLE 55 APTAMERS MARKET FOR CROS, BY REGION, 2019–2026 (USD MILLION) 90
TABLE 56 NORTH AMERICA: APTAMERS MARKET FOR CROS, BY COUNTRY,
2019–2026 (USD MILLION) 91
TABLE 57 EUROPE: APTAMERS MARKET FOR CROS, BY COUNTRY,
2019–2026 (USD MILLION) 91
TABLE 58 ASIA PACIFIC: APTAMERS MARKET FOR CROS, BY COUNTRY,
2019–2026 (USD MILLION) 92
9.5 OTHER END USERS 92
TABLE 59 APTAMERS MARKET FOR OTHER END USERS, BY REGION,
2019–2026 (USD MILLION) 92
TABLE 60 NORTH AMERICA: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 92
TABLE 61 EUROPE: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY,
2019–2026 (USD MILLION) 93
TABLE 62 ASIA PACIFIC: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 93

10 APTAMERS MARKET, BY REGION 94
10.1 INTRODUCTION 95
10.2 NORTH AMERICA 96
FIGURE 29 NORTH AMERICA: APTAMERS MARKET SNAPSHOT 96
TABLE 64 NORTH AMERICA: APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 97
TABLE 65 NORTH AMERICA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 66 NORTH AMERICA: APTAMERS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 97
TABLE 67 NORTH AMERICA: APTAMERS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 98
TABLE 68 NORTH AMERICA: APTAMERS MARKET, BY END USER,
2019–2026 (USD MILLION) 98
10.2.1 US 98
10.2.1.1 The US dominates the aptamers market 98
TABLE 69 US: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 99
TABLE 70 US: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 99
TABLE 71 US: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 99
TABLE 72 US: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 100
10.2.2 CANADA 100
10.2.2.1 Increasing government funding promotes market growth 100
TABLE 73 CANADA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 101
TABLE 74 CANADA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 101
TABLE 75 CANADA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 101
TABLE 76 CANADA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 102
10.3 EUROPE 102
TABLE 77 EUROPE: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 102
TABLE 78 EUROPE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 103
TABLE 79 EUROPE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 103
TABLE 80 EUROPE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 103
TABLE 81 EUROPE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 104
10.3.1 UK 104
10.3.1.1 Collaborative efforts for aptamer research and increasing investment in aptamers to drive market growth 104
TABLE 82 UK: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 105
TABLE 83 UK: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 105
TABLE 84 UK: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 105
TABLE 85 UK: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 106
10.3.2 GERMANY 106
10.3.2.1 Germany has reported a significant increase in aptamer-related research 106
TABLE 86 GERMANY: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 106
TABLE 87 GERMANY: APTAMERS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 107
TABLE 88 GERMANY: APTAMERS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 107
TABLE 89 GERMANY: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 107
10.3.3 FRANCE 108
10.3.3.1 Rising investment in aptamer research to drive the market growth 108
TABLE 90 FRANCE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 91 FRANCE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 108
TABLE 92 FRANCE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 109
TABLE 93 FRANCE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 109
10.3.4 ITALY 109
10.3.4.1 Growth of the life science and pharmaceutical industry to expand the market in Italy 109
TABLE 94 ITALY: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
TABLE 95 ITALY: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 110
TABLE 96 ITALY: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 110
TABLE 97 ITALY: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 111
10.3.5 SPAIN 111
10.3.5.1 Increased R&D funding in aptamer research to maximize market growth 111
TABLE 98 SPAIN: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 112
TABLE 99 SPAIN: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 112
TABLE 100 SPAIN: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 112
TABLE 101 SPAIN: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 113
10.3.6 REST OF EUROPE 113
TABLE 102 REST OF EUROPE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 103 REST OF EUROPE: APTAMERS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 114
TABLE 104 REST OF EUROPE: APTAMERS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 114
TABLE 105 REST OF EUROPE: APTAMERS MARKET, BY END USER,
2019–2026 (USD MILLION) 114
10.4 ASIA PACIFIC 115
FIGURE 30 ASIA PACIFIC: APTAMERS MARKET SNAPSHOT 115
TABLE 106 ASIA PACIFIC: APTAMERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 116
TABLE 107 ASIA PACIFIC: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 108 ASIA PACIFIC: APTAMERS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 116
TABLE 109 ASIA PACIFIC: APTAMERS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 117
TABLE 110 ASIA PACIFIC: APTAMERS MARKET, BY END USER,
2019–2026 (USD MILLION) 117
10.4.1 CHINA 117
TABLE 111 CHINA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 118
TABLE 112 CHINA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 118
TABLE 113 CHINA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 118
TABLE 114 CHINA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 119
10.4.2 JAPAN 119
10.4.2.1 Collaborative efforts by market players will propel market growth in Japan 119
TABLE 115 JAPAN: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 120
TABLE 116 JAPAN: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 120
TABLE 117 JAPAN: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 120
TABLE 118 JAPAN: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 121
10.4.3 INDIA 121
10.4.3.1 Government initiatives and increased disease burden to boost the market growth 121
TABLE 119 INDIA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 122
TABLE 120 INDIA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 122
TABLE 121 INDIA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 122
TABLE 122 INDIA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 123
10.4.4 ROAPAC 123
TABLE 123 ROAPAC: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 124 ROAPAC: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 124
TABLE 125 ROAPAC: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 124
TABLE 126 ROAPAC: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 124
10.5 LATIN AMERICA 125
10.5.1 INCREASE IN R&D EXPENDITURE TO SUPPORT THE MARKET GROWTH 125
TABLE 127 LATIN AMERICA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 128 LATIN AMERICA: APTAMERS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 125
TABLE 129 LATIN AMERICA: APTAMERS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 126
TABLE 130 LATIN AMERICA: APTAMERS MARKET, BY END USER,
2019–2026 (USD MILLION) 126
10.6 MIDDLE EAST & AFRICA 127
10.6.1 APTAMER RESEARCH AND INCREASING BURDEN OF CANCER TO PROMOTE MARKET GROWTH 127
TABLE 131 LUNG CANCER EPIDEMIOLOGY IN MIDDLE EAST COUNTRIES IN 2018 127
TABLE 132 MEA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 127
TABLE 133 MEA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 128
TABLE 134 MEA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 128
TABLE 135 MEA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION) 128

11 COMPETITIVE LANDSCAPE 129
11.1 INTRODUCTION 129
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 129
FIGURE 31 APTAMERS MARKET: STRATEGIES ADOPTED 130
11.3 MARKET RANKING ANALYSIS 131
FIGURE 32 APTAMERS MARKET RANKING ANALYSIS, BY KEY PLAYER, 2020 131
11.4 COMPANY EVALUATION MATRIX 132
11.4.1 STARS 132
11.4.2 EMERGING LEADERS 132
11.4.3 PERVASIVE PLAYERS 132
11.4.4 PARTICIPANTS 133
FIGURE 33 APTAMERS MARKET: COMPANY EVALUATION MATRIX, 2020 133
11.5 COMPETITIVE BENCHMARKING 134
11.5.1 COMPANY FOOTPRINT (10 COMPANIES) 134
FIGURE 34 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET 134
11.5.2 COMPANY PRODUCT & SERVICE FOOTPRINT (10 COMPANIES) 135
TABLE 136 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET 135
11.5.3 COMPANY TECHNOLOGY FOOTPRINT (10 COMPANIES) 135
TABLE 137 TECHNOLOGY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET 135
11.5.4 COMPANY APPLICATION FOOTPRINT (10 COMPANIES) 136
TABLE 138 APPLICATION FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET 136
11.5.5 COMPANY END-USER FOOTPRINT (10 COMPANIES) 136
TABLE 139 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET 136
11.6 COMPETITIVE SCENARIO AND TRENDS 137
11.6.1 PRODUCT & SERVICE LAUNCHES 137
TABLE 140 APTAMERS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2019–AUGUST 2021 137
11.6.2 DEALS 137
TABLE 141 APTAMERS MARKET: DEALS, JANUARY 2017–AUGUST 2021 137
12 COMPANY PROFILES 139
12.1 KEY COMPANIES 139
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 APTAMER GROUP 139
TABLE 142 APTAMER GROUP: BUSINESS OVERVIEW 139
TABLE 143 APTAMER GROUP: PRODUCT/SERVICE OFFERINGS 139
TABLE 144 APTAMER GROUP: DEALS 140
12.1.2 RAPTAMER DISCOVERY GROUP 143
TABLE 145 RAPTAMER DISCOVERY GROUP: BUSINESS OVERVIEW 143
TABLE 146 RAPTAMER DISCOVERY GROUP: PRODUCT OFFERINGS 143
12.1.3 SOMALOGIC, INC. 145
TABLE 147 SOMALOGIC, INC.: BUSINESS OVERVIEW 145
TABLE 148 SOMALOGIC, INC.: PRODUCT OFFERINGS 145
TABLE 149 SOMALOGIC, INC.: PRODUCT LAUNCHES 146
TABLE 150 SOMALOGIC, INC.: DEALS 146
TABLE 151 SOMALOGIC, INC.: OTHER DEVELOPMENTS 148
12.1.4 APTAMER SCIENCES, INC. 149
TABLE 152 APTAMER SCIENCES, INC.: BUSINESS OVERVIEW 149
FIGURE 35 APTAMER SCIENCES, INC.: COMPANY SNAPSHOT 149
TABLE 153 APTAMER SCIENCES, INC.: PRODUCT/SERVICE OFFERINGS 150
TABLE 154 APTAMER SCIENCES, INC.: PRODUCT APPROVALS 150
TABLE 155 APTAMER SCIENCES, INC.: DEALS 151
12.1.5 APTAGEN, LLC 153
TABLE 156 APTAGEN, LLC: BUSINESS OVERVIEW 153
TABLE 157 APTAGEN, LLC: PRODUCT/SERVICE OFFERINGS 153
TABLE 158 APTAGEN, LLC: DEALS 154
12.1.6 MARAVAI LIFESCIENCES 155
TABLE 159 MARAVAI LIFESCIENCES: BUSINESS OVERVIEW 155
FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT 155
TABLE 160 MARAVAI LIFESCIENCES: SERVICE OFFERINGS 156
12.1.7 KANEKA CORPORATION 157
TABLE 161 KANEKA CORPORATION: BUSINESS OVERVIEW 157
FIGURE 37 KANEKA CORPORATION: COMPANY SNAPSHOT 158
TABLE 162 KANEKA CORPORATION: SERVICE OFFERINGS 158
12.1.8 NEOVENTURES BIOTECHNOLOGY INC. 159
TABLE 163 NEOVENTURES BIOTECHNOLOGY INC.: BUSINESS OVERVIEW 159
TABLE 164 NEOVENTURES BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERINGS 159
12.1.9 APTUS BIOTECH 160
TABLE 165 APTUS BIOTECH: BUSINESS OVERVIEW 160
TABLE 166 APTUS BIOTECH: PRODUCT/SERVICE OFFERINGS 160
12.1.10 BASE PAIR BIOTECHNOLOGIES 161
TABLE 167 BASE PAIR BIOTECHNOLOGIES: BUSINESS OVERVIEW 161
TABLE 168 BASE PAIR BIOTECHNOLOGIES: PRODUCT/SERVICE OFFERINGS 161
TABLE 169 BASE PAIR BIOTECHNOLOGIES: OTHER DEVELOPMENTS 161
12.1.11 AMSBIO 162
TABLE 170 AMSBIO: BUSINESS OVERVIEW 162
TABLE 171 AMSBIO: PRODUCT/SERVICE OFFERINGS 162
12.1.12 NOVAPTECH 163
TABLE 172 NOVAPTECH: BUSINESS OVERVIEW 163
TABLE 173 NOVAPTECH: SERVICE OFFERINGS 163
TABLE 174 NOVAPTECH: DEALS 164
12.1.13 BIO-TECHNE 165
TABLE 175 BIO-TECHNE: BUSINESS OVERVIEW 165
FIGURE 38 BIO-TECHNE: COMPANY SNAPSHOT 166
TABLE 176 BIO-TECHNE: PRODUCT OFFERINGS 166
12.1.14 APTITUDE MEDICAL SYSTEMS 167
TABLE 177 APTITUDE MEDICAL SYSTEMS: BUSINESS OVERVIEW 167
TABLE 178 APTITUDE MEDICAL SYSTEMS: PRODUCT OFFERINGS 167
TABLE 179 APTITUDE MEDICAL SYSTEMS: DEALS 168
12.1.15 RAYBIOTECH, INC. 169
TABLE 180 RAYBIOTECH, INC.: BUSINESS OVERVIEW 169
TABLE 181 RAYBIOTECH, INC.: PRODUCT/SERVICE OFFERINGS 169
12.1.16 ALPHA DIAGNOSTIC INTERNATIONAL, INC. 170
TABLE 182 ALPHA DIAGNOSTIC INTERNATIONAL, INC.: BUSINESS OVERVIEW 170
TABLE 183 ALPHA DIAGNOSTIC INTERNATIONAL, INC.: PRODUCT OFFERINGS 170
12.1.17 CREATIVE BIOLABS 171
TABLE 184 CREATIVE BIOLABS: BUSINESS OVERVIEW 171
TABLE 185 CREATIVE BIOLABS: PRODUCT/SERVICE OFFERINGS 171
12.1.18 CREATIVE BIOGENE 172
TABLE 186 CREATIVE BIOGENE: BUSINESS OVERVIEW 172
TABLE 187 CREATIVE BIOGENE: PRODUCT/SERVICE OFFERINGS 172
12.1.19 VIVONICS INC. 173
TABLE 188 VIVONICS INC: BUSINESS OVERVIEW 173
TABLE 189 VIVONICS INC: PRODUCT/SERVICE OFFERINGS 173
12.1.20 IBA LIFESCIENCES GMBH 174
TABLE 190 IBA LIFESCIENCES GMBH: BUSINESS OVERVIEW 174
TABLE 191 IBA LIFESCIENCES GMBH: PRODUCT/SERVICE OFFERINGS 174
12.2 OTHER PLAYERS 175
12.2.1 APTABHARAT INNOVATIONS PVT. LTD 175
TABLE 192 APTABHARAT INNOVATIONS: COMPANY OVERVIEW 175
12.2.2 PROFACGEN 175
TABLE 193 PROFACGEN: COMPANY OVERVIEW 175
12.2.3 MEDIVEN 175
TABLE 194 MEDIVEN: COMPANY OVERVIEW 175
12.2.4 PURE BIOLOGICS SA 176
TABLE 195 PURE BIOLOGICS SA: COMPANY OVERVIEW 176
12.2.5 OAK BIOSCIENCES, INC. 176
TABLE 196 OAK BIOSCIENCES, INC.: COMPANY OVERVIEW 176
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX 177
13.1 DISCUSSION GUIDE 177
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 180
13.3 AVAILABLE CUSTOMIZATIONS 182
13.4 RELATED REPORTS 182
13.5 AUTHOR DETAILS 183

お問合せフォーム